Publication

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study

van Zeijl, M. C. T., Boer, F. L., van Poelgeest, M. I. E., van den Eertwegh, A. J. M., Wouters, M. W. J. M., de Wreede, L. C., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Ten Tije, A. J., van der Veldt, A. A. M., Vreugdenhil, G., Boers-Sonderen, M. J., Kapiteijn, E. H. W. & Haanen, J. B. A. G., Sep-2020, In : European Journal of Cancer. 137, p. 127-135 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Zeijl, M. C. T., Boer, F. L., van Poelgeest, M. I. E., van den Eertwegh, A. J. M., Wouters, M. W. J. M., de Wreede, L. C., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Ten Tije, A. J., van der Veldt, A. A. M., Vreugdenhil, G., Boers-Sonderen, M. J., Kapiteijn, E. H. W., & Haanen, J. B. A. G. (2020). Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. European Journal of Cancer, 137, 127-135. https://doi.org/10.1016/j.ejca.2020.05.021

Author

van Zeijl, Michiel C T ; Boer, Florine L ; van Poelgeest, Mariëtte I E ; van den Eertwegh, Alfons J M ; Wouters, Michel W J M ; de Wreede, Liesbeth C ; Aarts, Maureen J B ; van den Berkmortel, Franchette W P J ; de Groot, Jan Willem B ; Hospers, Geke A P ; Piersma, Djura ; van Rijn, Rozemarijn S ; Suijkerbuijk, Karijn P M ; Ten Tije, Albert J ; van der Veldt, Astrid A M ; Vreugdenhil, Gerard ; Boers-Sonderen, Marye J ; Kapiteijn, Ellen H W ; Haanen, John B A G. / Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. In: European Journal of Cancer. 2020 ; Vol. 137. pp. 127-135.

Harvard

van Zeijl, MCT, Boer, FL, van Poelgeest, MIE, van den Eertwegh, AJM, Wouters, MWJM, de Wreede, LC, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, JWB, Hospers, GAP, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Ten Tije, AJ, van der Veldt, AAM, Vreugdenhil, G, Boers-Sonderen, MJ, Kapiteijn, EHW & Haanen, JBAG 2020, 'Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study', European Journal of Cancer, vol. 137, pp. 127-135. https://doi.org/10.1016/j.ejca.2020.05.021

Standard

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. / van Zeijl, Michiel C T; Boer, Florine L; van Poelgeest, Mariëtte I E; van den Eertwegh, Alfons J M; Wouters, Michel W J M; de Wreede, Liesbeth C; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan Willem B; Hospers, Geke A P; Piersma, Djura; van Rijn, Rozemarijn S; Suijkerbuijk, Karijn P M; Ten Tije, Albert J; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Boers-Sonderen, Marye J; Kapiteijn, Ellen H W; Haanen, John B A G.

In: European Journal of Cancer, Vol. 137, 09.2020, p. 127-135.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Zeijl MCT, Boer FL, van Poelgeest MIE, van den Eertwegh AJM, Wouters MWJM, de Wreede LC et al. Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. European Journal of Cancer. 2020 Sep;137:127-135. https://doi.org/10.1016/j.ejca.2020.05.021


BibTeX

@article{7cfcdeccd48f4e4fa8042026d6454442,
title = "Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study",
abstract = "BACKGROUND: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM).METHODS: Patients with advanced MM and CM diagnosed between 2013 and 2017 were included from a nationwide population-based registry - the Dutch Melanoma Treatment Registry. Overall survival (OS) was estimated with the Kaplan-Meier method (also for a propensity score-matched cohort). A Cox model was used to analyse the association of possible prognostic factors with OS.RESULTS: In total, 120 patients with MM and 2960 patients with CM were included. Median OS was 8.7 months and 14.5 months, respectively. Patients with MM were older (median age 70 versus 65 years) and more often female (60% versus 41%), compared with CM. In total, 77% and 2% of the MM patients were treated with first-line immunotherapy and targeted therapy, respectively, compared with 49% and 33% of the CM patients. In contrast to CM, OS for MM did not improve for patients diagnosed in 2015-2017, compared with 2013-2014. ECOG performance score ≥1 (HR = 1.99 [1.26-3.15; p = 0.003]) and elevated LDH level (HR = 1.63 [0.96-2.76]; p = 0.069) in MM were associated with worse survival.CONCLUSIONS: Within the era of immune and targeted therapies, prognosis for patients with advanced MM has not improved as much as for CM. Collaboration is necessary to enlarge sample size for research to improve immunotherapeutic strategies and identify targetable mutations.",
author = "{van Zeijl}, {Michiel C T} and Boer, {Florine L} and {van Poelgeest}, {Mari{\"e}tte I E} and {van den Eertwegh}, {Alfons J M} and Wouters, {Michel W J M} and {de Wreede}, {Liesbeth C} and Aarts, {Maureen J B} and {van den Berkmortel}, {Franchette W P J} and {de Groot}, {Jan Willem B} and Hospers, {Geke A P} and Djura Piersma and {van Rijn}, {Rozemarijn S} and Suijkerbuijk, {Karijn P M} and {Ten Tije}, {Albert J} and {van der Veldt}, {Astrid A M} and Gerard Vreugdenhil and Boers-Sonderen, {Marye J} and Kapiteijn, {Ellen H W} and Haanen, {John B A G}",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = sep,
doi = "10.1016/j.ejca.2020.05.021",
language = "English",
volume = "137",
pages = "127--135",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",

}

RIS

TY - JOUR

T1 - Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study

AU - van Zeijl, Michiel C T

AU - Boer, Florine L

AU - van Poelgeest, Mariëtte I E

AU - van den Eertwegh, Alfons J M

AU - Wouters, Michel W J M

AU - de Wreede, Liesbeth C

AU - Aarts, Maureen J B

AU - van den Berkmortel, Franchette W P J

AU - de Groot, Jan Willem B

AU - Hospers, Geke A P

AU - Piersma, Djura

AU - van Rijn, Rozemarijn S

AU - Suijkerbuijk, Karijn P M

AU - Ten Tije, Albert J

AU - van der Veldt, Astrid A M

AU - Vreugdenhil, Gerard

AU - Boers-Sonderen, Marye J

AU - Kapiteijn, Ellen H W

AU - Haanen, John B A G

N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM).METHODS: Patients with advanced MM and CM diagnosed between 2013 and 2017 were included from a nationwide population-based registry - the Dutch Melanoma Treatment Registry. Overall survival (OS) was estimated with the Kaplan-Meier method (also for a propensity score-matched cohort). A Cox model was used to analyse the association of possible prognostic factors with OS.RESULTS: In total, 120 patients with MM and 2960 patients with CM were included. Median OS was 8.7 months and 14.5 months, respectively. Patients with MM were older (median age 70 versus 65 years) and more often female (60% versus 41%), compared with CM. In total, 77% and 2% of the MM patients were treated with first-line immunotherapy and targeted therapy, respectively, compared with 49% and 33% of the CM patients. In contrast to CM, OS for MM did not improve for patients diagnosed in 2015-2017, compared with 2013-2014. ECOG performance score ≥1 (HR = 1.99 [1.26-3.15; p = 0.003]) and elevated LDH level (HR = 1.63 [0.96-2.76]; p = 0.069) in MM were associated with worse survival.CONCLUSIONS: Within the era of immune and targeted therapies, prognosis for patients with advanced MM has not improved as much as for CM. Collaboration is necessary to enlarge sample size for research to improve immunotherapeutic strategies and identify targetable mutations.

AB - BACKGROUND: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM).METHODS: Patients with advanced MM and CM diagnosed between 2013 and 2017 were included from a nationwide population-based registry - the Dutch Melanoma Treatment Registry. Overall survival (OS) was estimated with the Kaplan-Meier method (also for a propensity score-matched cohort). A Cox model was used to analyse the association of possible prognostic factors with OS.RESULTS: In total, 120 patients with MM and 2960 patients with CM were included. Median OS was 8.7 months and 14.5 months, respectively. Patients with MM were older (median age 70 versus 65 years) and more often female (60% versus 41%), compared with CM. In total, 77% and 2% of the MM patients were treated with first-line immunotherapy and targeted therapy, respectively, compared with 49% and 33% of the CM patients. In contrast to CM, OS for MM did not improve for patients diagnosed in 2015-2017, compared with 2013-2014. ECOG performance score ≥1 (HR = 1.99 [1.26-3.15; p = 0.003]) and elevated LDH level (HR = 1.63 [0.96-2.76]; p = 0.069) in MM were associated with worse survival.CONCLUSIONS: Within the era of immune and targeted therapies, prognosis for patients with advanced MM has not improved as much as for CM. Collaboration is necessary to enlarge sample size for research to improve immunotherapeutic strategies and identify targetable mutations.

U2 - 10.1016/j.ejca.2020.05.021

DO - 10.1016/j.ejca.2020.05.021

M3 - Article

C2 - 32763783

VL - 137

SP - 127

EP - 135

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

ID: 134207109